BREAKING: Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression

"After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization."

Resource Link for BREAKING: Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression (opens new window)

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR), with nearly half of cancer patients (48.4%) reporting either no evidence of disease (32.8%) or tumor regression (15.6%). An additional 36.1% reported disease stabilization. This means more than four out of five patients reported either improvement or stabilization of their cancer.